Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about INDV, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Buprenorphine FDA approved Nov 2017 · Sublocade |
Opioid Dependence | Phase 4 · NCT02038790 | Completed |
| Buprenorphine Hydrochloride FDA approved Dec 1981 · Buprenex (discontinued) |
Opiate Dependence | Phase 4 · NCT00605033 | Completed |
| Buprenorphine Hydrochloride, Naloxone… | Hepatic Failure | Phase 4 · NCT01846455 | Completed |
| Transmucosal Buprenorphine | Moderate to Severe Opioid-use Disorder | Phase 4 · NCT04995029 | Completed |
| Naloxone | Opiate Dependence | Phase 4 · NCT00605033 | Completed |
| Promethazine | Hepatic Failure | Phase 4 · NCT01846455 | Completed |
| PERSERIS | Schizophrenia | Phase 4 · NCT03978832 | Completed |
| RBP-7000 | Schizophrenia | Phase 3 · NCT02109562 | Completed |
| Intranasal challenge drug | Heroin Dependence | Phase 3 · NCT01760473 | Completed |
| RBP-6000 | Opioid Use Disorder | Phase 3 · NCT02896296 | Completed |
| XP19986 CR | GERD | Phase 2 · NCT00838396 | Completed |
| Arbaclofen Placarbil | Alcohol Use Disorder | Phase 2 · NCT02511886 | Completed |
| RBP-8000 100 mg | Opioid Dependence | Phase 2 · NCT01846481 | Completed |
| RBP-6300 | Opioid Related Disorder | Phase 2 · NCT01582347 | Completed |
| Buprenorphine hydrochloride fast dissolving… | Opioid Dependency | Phase 2 · NCT01075971 | Completed |
| INDV-6001 | Moderate to Severe Opioid Use Disorder | Phase 2 · NCT06576843 | Completed |
Also used in these trials (approved or third-party drugs, not INDV's own candidates): Risperidone, Buprenorphine And Naloxone, Midazolam Hydrochloride, Ondansetron - Parts A + B.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
INDV holds $305M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when INDV files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BlackRock, Inc. | Institution (13G, 5%+) | 17,806,183 | 15.09% | 2025-12-31 |
| Vanguard Portfolio Management | Institution (13G, 5%+) | 7,994,836 | 6.77% | 2026-03-31 |
| Vanguard Capital Management | Institution (13G, 5%+) | 6,523,720 | 5.53% | 2026-03-31 |
| Millennium Management LLC | 5%+ holder (13G) | 6,343,651 | 5.37% | 2026-09-23 |
| Jack A. Khattar Chief Executive Officer, Director · +4.00M options |
Insider | 3,413,555 | 2.89% | 2026-11-02 |
| Joseph Ciaffoni Chief Executive Officer, Director |
Insider | 790,330 | 0.67% | 2026-06-22 |
| Ryan Preblick Chief Financial Officer |
Insider | 284,751 | 0.24% | 2026-06-08 |
| Christian Heidbreder Chief Scientific Officer |
Insider | 209,337 | 0.18% | 2026-07-10 |
| Jeffrey W Burris Chief Legal Officer |
Insider | 71,518 | 0.06% | 2026-03-03 |
| Georges Gemayel Director · +123,818 options |
Insider | 42,009 | 0.04% | 2026-11-02 |
| Carrolee Barlow Director · +116,987 options |
Insider | 41,652 | 0.04% | 2026-11-02 |
| Patrick A Barry Chief Commercial Officer |
Insider | 31,380 | 0.03% | 2026-02-10 |
Share count 118,035,272 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INDV and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →